CME Activities
Grand Rounds
Booth
Online Programs
Insights in Acute Myeloid Leukemia: Optimizing System Level Quality for Our Veterans
PROGRAM CHAIR & FACULTY PRESENTER
Michael R. Grunwald, MD
Chief, Leukemia Division
Director, Transplantation and Cellular Therapy Program
Associate Professor
Levine Cancer Institute, Atrium Health
Charlotte, NC
PROGRAM OVERVIEW
This activity will explore the management of patients with of newly diagnosed and relapsed/refractory acute myeloid leukemia (AML). This program will address the role of genetic and molecular markers in treatment selection as well as best practices for treatment of newly diagnosed, and relapsed/refractory, and secondary AML. A summary of approaches to TRAE recognition and mitigation will also be discussed.
TARGET AUDIENCE
This educational activity is intended for hematologists, community oncologists and clinicians involved in the assessment, monitoring, and treatment of AML in the Department of Veterans Affairs.
LEARNING OBJECTIVES
Upon completion of the program, attendees should be able to:
- Evaluate the role of genetic and molecular markers in treatment options for patients with AML
- Assess best practices for clinical management of newly diagnosed, and relapsed/refractory AML, as well as secondary AML, and implement shared decision-making across treatment plans
- Summarize possible adverse events associated with AML treatment and understand best practices for identification and management of potential adverse events
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with acute myeloid leukemia.
CNE Credits: 1.0 ANCC Contact Hour.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Dr. Grunwald has received consulting fees from AbbVie, Agios/Servier, Amgen, Astellas Pharma, Blueprint Medicines, Bristol Myers Squibb, Cardinal Health, CTI Biopharma, Daiichi Sankyo, Gamida Cell, Gilead Sciences, Incyte Corporation, Invitae, Novartis, Ono Pharmaceutical, Pfizer, Premier, Sierra Oncology, and Stemline; he has also been contracted for research with Janssen, and holds stock in Medtronic.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
James Seternus, DO, Medical & Scientific Services for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Jessica McMullen, MPH, Program Manager for Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures.
- Participate in the online activity.
- Complete the online post-test and evaluation.
You will receive your certificate as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at info@medlearninggroup.com.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
RELEASE DATE: May 26, 2022
EXPIRATION DATE: May 26, 2023
Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
MED GAMES: Insights from the Experts—Navigating the Complex and Evolving Landscape of CLL and AML
View Activity AML and CLL Med Games Toolkit Poster Portal
Extra Resources
Video Case Study 1 Video Case Study 2
FACULTY
|
Michael R. Grunwald, MD |
Ryan Jacobs, MD |
PROGRAM OVERVIEW
This activity will explore the management of patients with acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL), including the impact of molecular markers, genetic data, and patient characteristics on treatment selection; and potential adverse events of AML and CLL treatments.
TARGET AUDIENCE
This multi-modular educational initiative is intended for US-based hematologists, medical oncologists, and other healthcare providers involved in the management of patients with CLL and/or AML.
LEARNING OBJECTIVES
Upon completion of the program, attendees should be able to:
- Summarize the relevance of molecular markers and genetic data relevant to selection of therapy in CLL or AML
- Review relevant treatment best practices in both newly diagnosed and relapsed/refractory AML in consideration of disease- and patient-specific factors to inform shared decision-making
- Evaluate potential adverse events associated with CLL and AML therapies to implement appropriate monitoring and counseling
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this online activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with CLL and/or AML.
CNE Credits: 1.0 ANCC Contact Hour.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Michael R. Grunwald, MD, receives consulting fees from AbbVie, Agios/Servier, Amgen, Astellas Pharma, Blueprint Medicines, Bristol Myers Squibb, Cardinal Health, CTI Biopharma, Daiichi Sankyo, Gamida Cell, Gilead Sciences, Incyte Corporation, Invitae, Karius, Novartis, Ono Pharmaceutical, Pfizer, Premier, Sierra Oncology, and Stemline Therapeutics; he receives research funding (institution) from Janssen and has stock ownership in Medtronic.
Ryan Jacobs, MD, receives consulting fees from Adaptive, Genentech, MorphoSys, Secura Bio, and TG Therapeutics; he has served on the speaker’s bureau for AbbVie, AstraZeneca, Janssen, Pharmacyclics, Secura Bio, and TG Therapeutics. He has also received research funding from LOXO, MEI Pharma, Pharmacyclics, and Teneobio.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Angela L. Davis, PhD, Director, Medical & Scientific Services for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Jessica McMullen, MPH, Program Manager for Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures.
- Participate in the online activity.
- Complete the online post-test and evaluation.
You will receive your certificate as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
Copyright ©2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
View Activity AML and CLL Med Games Toolkit Poster Portal
Extra Resources
Video Case Study 1 Video Case Study 2
Approaches to Improving Care in Chronic Lymphocytic Leukemia in the Veteran’s Affairs System: Insights from the Experts
PROGRAM CHAIR & FACULTY PRESENTER
Ryan Jacobs, MD
Principal Investigator of CLL Clinical Trials
Assistant Professor, Atrium Health
Department of Hematology, Lymphoma Section
Levine Cancer Institute
Charlotte, NC
PROGRAM OVERVIEW
This activity will explore the management of patients with of treatment-naïve and relapsed/refractory chronic lymphocytic leukemia (CLL). This program will address approaches to individualize selection of therapy and the role of minimal residual disease (MRD) in monitoring treatment effectiveness. A summary of approaches to TRAE recognition and mitigation will also be addressed.
TARGET AUDIENCE
This educational activity is intended for hematologists, community oncologists and clinicians involved in the assessment, monitoring, and treatment of CLL in the Department of Veterans Affairs.
LEARNING OBJECTIVES
Upon completion of the program, attendees should be able to:
- Assess how genetic and molecular markers aid in determining treatment strategies for patients with CLL
- Evaluate the role of MRD in monitoring the effectiveness of treatment approaches for CLL and its clinical implications
- Individualize selection of therapies for the treatment of treatment-naïve and relapsed/refractory (R/R) CLL based on disease‐ and patient‐specific factors to communicate these treatment plans using shared decision-making strategies
- Recognize adverse events associated with CLL treatment to appropriately prevent and/or manage these potential effects
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with chronic lymphocytic leukemia.
CNE Credits: 1.0 ANCC Contact Hour.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Dr. Jacobs has received consulting fees from Secura Bio, Genentech, Adaptive, TG Therapeutics, and MorphoSys; he has served on the speaker’s bureau for Pharmacyclics, Janssen, AbbVie, TG Therapeutics, Secura Bio, and AstraZeneca. He has also received research funding from Pharmacyclics, Teneobio, MEI Pharma, and LOXO.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- James Seternus, DO, Medical & Scientific Services for Med Learning Group has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Jessica McMullen, MPH, Program Manager for Med Learning Group, has nothing to disclose.
- Russie Allen, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
- Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures.
- Participate in the online activity.
- Complete the online post-test and evaluation.
You will receive your certificate as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy‐policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
RELEASE DATE: July 07, 2022
EXPIRATION DATE: July 07, 2023
Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
Optimizing the Care of Patients with Relapsed/Refractory MCL and CLL/SLL in the Veteran’s Administration System: Evaluating Evidence-Based Management
PROGRAM CHAIR & FACULTY PRESENTER
Ryan Jacobs, MD
Department of Hematology, Lymphoma Division
Assistant Professor of Medicine
Levine Cancer Institute/Atrium Health
Charlotte, NC
PROGRAM OVERVIEW
This activity will explore emerging treatment options and novel management strategies of patients with relapsed/refractory MCL or CLL/SLL.
TARGET AUDIENCE
This activity is designed to meet the educational needs of hematologists, oncologists, and other community-based healthcare practitioners who care for patients with MCL and CLL/SLL within the Veterans Affairs health system.
LEARNING OBJECTIVES
Upon completion of the program, attendees should be able to:
- Examine needs for immunophenotyping and evaluation of genetic data to inform CLL/SLL and MCL management in the first-line setting and beyond
- Consider efficacy and safety data with emerging therapies for CLL/SLL and MCL management in consideration of current guidelines
- Discuss unique mechanistic features of specific therapies, as well as adverse event profiles and the rationale for use in relapsed/refractory patients
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with relapsed/refractory mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL).
CNE Credits: 1.0 ANCC Contact Hour.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Ryan Jacobs, MD, receives consulting fees from Adaptive, Genentech, MorphoSys, Secura Bio, and TG Therapeutics; he has served on the speaker’s bureau for AbbVie, AstraZeneca, Janssen, Pharmacyclics, Secura Bio, and TG Therapeutics. He has also received research funding from LOXO, MEI Pharma, Pharmacyclics, and Teneobio.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- James Seternus, DO, Medical & Scientific Services for Med Learning Group has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Jessica McMullen, MPH, Program Manager for Med Learning Group, has nothing to disclose.
- Russie Allen, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
- Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures.
- Participate in the online activity.
- Complete the online post-test and evaluation.
You will receive your certificate as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy‐policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
RELEASE DATE: August 03, 2022
EXPIRATION DATE: August 03, 2023
Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
Summit Meetings
TeleECHOs
